Amgen’s Imdelltra (tarlatamab) plus AstraZeneca’s Imfinzi (durvalumab) met the primary overall survival endpoint in a phase III study of first-line maintenance therapy for adults with extensive-stage small-cell lung cancer, according to the report. The result positions the regimen as a potential option after initial treatment, aiming to improve durability of response in a disease area where long-term outcomes remain limited. For biopharma executives, the impact is twofold: a new combination strategy in a high-need oncology segment and an additional read-through for how bispecific and PD-L1 approaches might combine for maintenance settings—an area regulators and payers scrutinize for magnitude and consistency of benefit.